European Atherosclerosis Society (EAS) & Congress

European Atherosclerosis Society (EAS) & Congress For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis.

The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS contributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders. In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines. What we do
The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into perspective topical issues of relevance to our members. The Society organizes an annual Congress for approximately 2000 delegates, and runs a programme of Advanced Courses for both basic scientists and clinicians. EAS Academy is the Society's online e-Learning resource, containing a range of educational material and self-teaching programmes.

Encourage your patients with elevated Lp(a) levels to maintain a healthy lifestyle, and make sure you also learn more ab...
25/03/2026

Encourage your patients with elevated Lp(a) levels to maintain a healthy lifestyle, and make sure you also learn more about lipoprotein(a) through our educational resources: https://eas.to/LpaD2026

The International Study on the cost-effectiveness of Lp(a) testing shows that using Lp(a) to reclassify cardiovascular d...
24/03/2026

The International Study on the cost-effectiveness of Lp(a) testing shows that using Lp(a) to reclassify cardiovascular disease (CVD) risk in the primary prevention population aged 40–69 years is a highly cost-effective way to prevent CVD.

Implementing Lp(a) testing is not only strongly justified from a clinical perspective, but is also likely to deliver a financial return on investment when considered from a societal perspective.

These results support the immediate implementation of Lp(a) testing in primary prevention populations in high-income countries.

Learn more about this study and other Lp(a)-related initiatives here: https://eas.to/LpaD2026

Only 1-2% of the population has had an Lp(a) measurement and therefore most of those with elevated concentrations do not...
24/03/2026

Only 1-2% of the population has had an Lp(a) measurement and therefore most of those with elevated concentrations do not know about their increased levels. Remember that Lp(a) should be measured at least once in life to identify those with a high CV risk. Help us increase awareness & promote education by learning from our dedicated website: https://eas.to/LpaD2026

Last Chance to Save on Registration! Today is your final opportunity to register and secure the early bird rate for th...
24/03/2026

Last Chance to Save on Registration!

Today is your final opportunity to register and secure the early bird rate for the 94th EAS Congress in Athens. After today, ticket prices will increase, so don’t miss out on your chance to save!
🔗 https://bit.ly/4qtiFEi

Join us in a shared mission to raise awareness, expand understanding, and drive meaningful change in health outcomes rel...
24/03/2026

Join us in a shared mission to raise awareness, expand understanding, and drive meaningful change in health outcomes related to Lp(a). On the occasion of Lp(a) Awareness Day, we have brought together key resources and learning opportunities to inform, inspire, and empower you: https://eas.to/LpaD2026

The discourse on Lp(a) among many stakeholders across the globe (medical societies, healthcare professionals, academics/...
23/03/2026

The discourse on Lp(a) among many stakeholders across the globe (medical societies, healthcare professionals, academics/researchers, patient organisations and life sciences industry) points to the urgent need to encourage a more systematic and structured approach to testing the population, following guidelines, to decrease the overall cardiovascular disease (CVD) risk / prevent CVD from high levels of Lp(a).

Recommendations and guidelines such as the EAS Lipoprotein(a) 2022 Consensus Statement underline that everyone should be tested once in a lifetime.

This webinar will explore how healthy, sustainable dietary patterns can help prevent cardiovascular disease (CVD), while...
21/03/2026

This webinar will explore how healthy, sustainable dietary patterns can help prevent cardiovascular disease (CVD), while also introducing the rapidly evolving field of precision nutrition for cardiometabolic health. Join leading experts as they share the latest research and practical strategies for improving heart health through diet: https://eas.to/WebDiet3

The new AtheroTalk episode is out! We were honored to host Prof. John J.P. Kastelein, one of the most influential figure...
19/03/2026

The new AtheroTalk episode is out! We were honored to host Prof. John J.P. Kastelein, one of the most influential figures in lipidology and cardiovascular prevention.

With a career spanning decades of groundbreaking research and innovation, Prof. Kastelein shares his personal journey and reflects on the evolution of lipid-lowering therapy — from the early days of statins to today’s rapidly expanding pipeline of novel therapeutics.

Together, we explore the milestones that have shaped modern cardiovascular prevention, the lessons learned along the way, and the exciting future of precision lipid management. This conversation offers unique insights into the intersection of science, clinical practice, and drug development, from someone who has been at the forefront of it all.

🎧 Spotify: https://eas.to/ATHTalkE29S
🎧 Apple Podcasts: https://eas.to/ATHTalkE29A
🎧 Youtube: https://eas.to/ATHTalkE29Y

Plenary 02: Advances in Atherosclerosis & Cardiovascular Disease at !In Plenary 2, leading experts will explore the lat...
19/03/2026

Plenary 02: Advances in Atherosclerosis & Cardiovascular Disease at !

In Plenary 2, leading experts will explore the latest breakthroughs in atherosclerosis and cardiovascular disease:

✅ M. L. Brown – New Insights into Cholesterol Metabolism
Dr. Brown will share recent discoveries in cholesterol metabolism and their implications for cardiovascular health.

✅ L. S. Parra – Gene Therapy for Atherosclerosis
Dr. Parra will discuss the potential of gene therapy as a treatment for atherosclerosis, offering targeted solutions for disease management.

✅ K. T. Ito – Cardiovascular Risk Factors and Management
Dr. Ito will explore innovative approaches to managing cardiovascular risk factors to improve patient outcomes.

✅ P. M. Green – Inflammation in Cardiovascular Disease
Dr. Green will highlight the role of inflammation in cardiovascular disease and how targeting inflammation could lead to new treatments.

🎉 We are pleased to announce this year’s Young Investigator Award winners. The Basic Science Award goes to Annalaura Mas...
17/03/2026

🎉 We are pleased to announce this year’s Young Investigator Award winners. The Basic Science Award goes to Annalaura Mastrangelo (CNIC, Madrid) for “Imidazole propionate is a driver and therapeutic target in atherosclerosis,” and the Clinical Science Award to Nick Nurmohamed (Amsterdam UMC) for “First myocardial infarction: risk factors, symptoms, and medical therapy.” Read more: https://eas.to/YIA2026Res

The second webinar of the series will explore the latest research on the role of omega-3 fatty acids in cardiovascular h...
16/03/2026

The second webinar of the series will explore the latest research on the role of omega-3 fatty acids in cardiovascular health. Leading experts will share their insights on how icosapent ethyl and marine omega-3 fatty acids influence lipoprotein remodeling and cardiovascular disease (CVD) risk markers, especially in normolipidemic individuals. Join us and register now: https://eas.to/WebDiet2

Adress

Första Långgatan 4A
Gothenburg
41303

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när European Atherosclerosis Society (EAS) & Congress postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till European Atherosclerosis Society (EAS) & Congress:

Genvägar

Dela

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram